You are here: Industry Insights > Market News > M&As this week: Catalent, Ultragenyx Pharmaceutical

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

M&As this week: Catalent, Ultragenyx Pharmaceutical

pharmaceufical-technologySeptember 25, 2017

Tag: Catalent , Ultragenyx , pharmaceutical

Favorites

Catalent has announced plans to acquire Cook Pharmica for $950m.

The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.

Both the acquirer and target entities are pharmaceutical companies based in the US.

"Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m."

Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.

The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.

Both companies involved in the acquisition are based in the US.

Previous:Novartis’ Rydapt receives approval for two cancer treatments in the EU

Next:AbbVie, Bristol-Myers Squibb Announce Clinical Research Collaboration

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

M&As this week: Catalent, Ultragenyx Pharmaceutical | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Ellagic acid ≥90.0% supplier API Plant extract Pharmaceutical made in china

Pharmaceutical Packaging Series Oral Liquid Packaging Box Blister Tray

Specializing in the production of plastic products, pharmaceutical plastic trays, food plastic trays

Pharmaceutical Chemical High Quality Tofacitinib Citrate CAS 540737-29-9

Lornoxicam other active pharmaceutical ingredients

Oxyresveratrol 98% Plant extract Pharmaceutical supplier made in china

Pharmaceutical Grade API Atomoxetine Hydrochloride CAS 82248-59-7

Anisomycin 98%min pharmaceuticals supply in China

pharmaceutical Bivalirudin-peptide

Albendazole CP/USP pharmaceutical China supplier for veterinary

M&As this week: Catalent, Ultragenyx Pharmaceutical

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>